In the ToGA trial, compared with chemotherapy alone, the treatments combining the anti-HER2 monoclonal antibody trastuzumab with chemotherapy showed a significantly favorable prognosis in patients with HER2-positive GC (Bang et al., 2010). Here, ERBB2 is linked to gastric cancer.